{"id":"oral-calcitonin-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcitonin is a peptide hormone that binds to calcitonin receptors expressed on osteoclasts, leading to their inactivation and apoptosis. This reduces bone resorption and helps maintain or increase bone mineral density. The oral formulation uses proprietary delivery technology to enable systemic absorption of this peptide hormone through the gastrointestinal tract.","oneSentence":"Oral calcitonin activates calcitonin receptors on osteoclasts to inhibit bone resorption and reduce bone loss.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:46.690Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Bone loss and fracture risk reduction"}]},"trialDetails":[{"nctId":"NCT03898856","phase":"PHASE4","title":"Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2019-04-01","conditions":"Chronic Diarrhea of Unknown Origin","enrollment":93},{"nctId":"NCT05217927","phase":"PHASE4","title":"Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-04","conditions":"Migraine","enrollment":1415},{"nctId":"NCT05895500","phase":"","title":"Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia","status":"COMPLETED","sponsor":"Nvision Laser Eye Centers","startDate":"2023-05-10","conditions":"Dry Eye, Asthenopia","enrollment":103},{"nctId":"NCT05632133","phase":"PHASE3","title":"The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-06-01","conditions":"Effect of Drug, Migraine Disorders","enrollment":200},{"nctId":"NCT03828539","phase":"PHASE4","title":"Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-22","conditions":"Migraine","enrollment":777},{"nctId":"NCT03542357","phase":"NA","title":"The Effect of Sumatriptan and Placebo on CGRP Induced Headache","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2018-02-15","conditions":"Migraine","enrollment":30},{"nctId":"NCT01294709","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02-12","conditions":"Angina Pectoris, Coronary Heart Disease, Calcitonin Gene-related Peptide Receptor","enrollment":64},{"nctId":"NCT01292187","phase":"PHASE2","title":"A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Tarsa Therapeutics, Inc.","startDate":"2011-01","conditions":"Osteopenia","enrollment":129},{"nctId":"NCT00803686","phase":"PHASE2","title":"A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Tarsa Therapeutics, Inc.","startDate":"2008-12","conditions":"Phase 1 Pharmacodynamic Study","enrollment":12},{"nctId":"NCT01329562","phase":"PHASE4","title":"CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet","status":"COMPLETED","sponsor":"Cady, Roger, M.D.","startDate":"2011-05","conditions":"Menstrual Migraine","enrollment":41},{"nctId":"NCT00959764","phase":"PHASE3","title":"A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women","status":"COMPLETED","sponsor":"Tarsa Therapeutics, Inc.","startDate":"2009-06","conditions":"Osteoporosis, Postmenopausal","enrollment":565},{"nctId":"NCT00620854","phase":"PHASE2","title":"A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women","status":"COMPLETED","sponsor":"Tarsa Therapeutics, Inc.","startDate":"2008-02","conditions":"Osteoporosis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rsCT tablets"],"phase":"phase_3","status":"active","brandName":"Oral Calcitonin Tablets","genericName":"Oral Calcitonin Tablets","companyName":"Tarsa Therapeutics, Inc.","companyId":"tarsa-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral calcitonin activates calcitonin receptors on osteoclasts to inhibit bone resorption and reduce bone loss. Used for Osteoporosis in postmenopausal women, Bone loss and fracture risk reduction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}